Endoscopic gastric reduction for obesity treatment
Impact of Endoscopic Gastric Reduction of Ghrelin Receptors Rich Gastric Mucosa on Obesity and Metabolic Syndrome: a Randomized Controlled Trial
This study is testing if a new procedure that reduces stomach size can help people with obesity lose weight and improve their health by changing how their body controls hunger.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 48 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | All |
| Sponsor | Zagazig University Government |
| Locations | 1 site (Zagazig, Sharkia) |
| Trial ID | NCT06231251 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effects of endoscopic gastric reduction on the gastric mucosa in patients with obesity. The approach focuses on altering ghrelin secretion, a hormone that influences appetite and food intake, by targeting specific cells in the stomach. Participants will undergo upper gastrointestinal endoscopy to assess the impact of this intervention on their weight and metabolic health. The study aims to provide insights into how modifying gastric function can aid in obesity management.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals with a body mass index over 25 who also have diabetes mellitus, cardio-metabolic syndrome, or fatty liver disease.
Not a fit: Patients with chronic gastritis, active peptic ulcers, malignancies, or severe psychological disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could lead to a novel treatment option for obesity that helps regulate appetite and improve metabolic health.
How similar studies have performed: While there is ongoing research into ghrelin's role in obesity, this specific endoscopic approach is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * body mass index more than 25 * diagnosis of diabetes mellitus. * diagnosis of cardio-metabolic syndrome. * fatty liver disease diagnosed by abdominal ultrasound. Exclusion Criteria: * use of drugs which induce insulin resistance, diabetes and hepatic steatosis. * excess alcohol consumption. * chronic gastritis, active peptic ulcer. * malignancy. * depression and severe psychological disorders * inability to give informed consent. * coagulopathy (INR more than 1.5, platelets less than 50000 per cmm). * severe cardiopulmonary comorbidity.
Where this trial is running
Zagazig, Sharkia
- Zagazig University — Zagazig, Sharkia, Egypt (Recruiting)
Study contacts
- Study coordinator: Amr S Hanafy
- Email: amrhanafy@zu.edu.eg
- Phone: +201100061861
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.